Belite Bio Reports Q4 & FY 2024 Results
Ticker: BLTE · Form: 6-K · Filed: Mar 17, 2025 · CIK: 1889109
| Field | Detail |
|---|---|
| Company | Belite Bio, INC (BLTE) |
| Form Type | 6-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, corporate-update
TL;DR
Belite Bio dropped its Q4 and full-year 2024 financials on 3/17/25. Check the press release.
AI Summary
Belite Bio, Inc. announced its fourth quarter and full-year 2024 financial results on March 17, 2025. The company also provided a corporate update alongside the financial report. This 6-K filing incorporates the press release detailing these results and updates.
Why It Matters
This filing provides investors with the latest financial performance and strategic updates from Belite Bio, Inc., crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine financial results announcement and corporate update, not indicating any immediate material changes or risks.
Key Players & Entities
- Belite Bio, Inc. (company) — Registrant
- March 17, 2025 (date) — Date of press release and filing
- 001-41359 (other) — Commission File Number
FAQ
What is the title of the press release issued by Belite Bio, Inc. on March 17, 2025?
The press release is entitled "Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update".
What form is this SEC filing?
This is a Form 6-K report.
What is the Commission File Number for Belite Bio, Inc.?
The Commission File Number is 001-41359.
What period do the financial results reported cover?
The financial results reported cover the fourth quarter and full year 2024.
Where is Belite Bio, Inc. located?
Belite Bio, Inc.'s principal executive office is located at 12750 High Bluff Drive Suite 475, San Diego, CA 92130.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 17, 2025 regarding BELITE BIO, INC (BLTE).